Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.

Yelena Y. Janjigian,Akihito Kawazoe,Patricio Eduardo Yanez,Suxia Luo,Sara Lonardi,Oleksii Kolesnik,Olga Barajas,Yuxian Bai,Lin Shen,Yong Tang,Lucjan Wyrwicz,Kohei Shitara,Shukui Qin,Eric Van Cutsem,Josep Tabernero,Lie Li,Chie-Schin Shih,Pooja Bhagia,Hyun Cheol Chung

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.

2021

Yelena Y. Janjigian
Akihito Kawazoe
Patricio Eduardo Yanez
Suxia Luo
Sara Lonardi
Oleksii Kolesnik
Olga Barajas
Yuxian Bai
Lin Shen
Yong Tang
Lucjan Wyrwicz
Kohei Shitara
Shukui Qin
Eric Van Cutsem
Josep Tabernero
Lie Li
Chie-Schin Shih
Pooja Bhagia
Hyun Cheol Chung

4013Background: Trastuzumab (tras) plus chemotherapy (chemo) is standard-of-care (SOC) 1L therapy for HER2+ metastatic G/GEJ cancer. In two phase 2 studies, tras, chemo, and pembrolizumab (pembro) ...

Keywords:

Chemotherapy
Gastroesophageal Junction
Oncology
Cancer
Medicine
Pembrolizumab
Internal medicine
Trastuzumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations